Live In Play®
Updated: 20-Mar-26 06:01 ET
RYTM:  Rhythm Pharmaceuticals receives FDA approval for expanded IMCIVREE indication  (90.31)
  • Rhythm Pharmaceuticals Inc. announced FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity.
    • Co's therapy is now the first and only approved treatment for this rare condition.
    • Approval supported by Phase 3 data showing ~18.4% placebo-adjusted BMI reduction.
    • Label expands use to adults and children aged 4+, with immediate U.S. availability.
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.